News
The stable outlook reflects S&P Global Ratings’ expectation that Amgen’s revenue and EBITDA will remain stable despite patent ...
The table below is a review of notable updates that occurred in April 2025 for investigational products in development.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback